Showing 3721-3730 of 4063 results for "".
- The Lancet Withdraws Major Hydroxychloroquine Studyhttps://modernod.com/news/the-lancet-withdraws-controversial-hydroxychloroquine-study/2477866/A major study in the Lancet that suggested hydroxychloroquine was associated with higher rates of ventricular arrhythmia and death in COVID-19 patients has been retracted. The multinational registry analysis, published in the Lancet on May 22, included nearly 15,000 peopl
- Prevent Blindness to Host Ninth Annual Focus on Eye Health National Summit as an Online Virtual Eventhttps://modernod.com/news/prevent-blindness-to-host-ninth-annual-focus-on-eye-health-national-summit-as-an-online-virtual-event/2477861/Prevent Blindness will host the 9th annual Prevent Blindness Focus on Eye Health National Summit, on July 15, 2020, from 12-3 p.m. ET (a virtual exhibit hall will be open from 11 a.m.- 4 p.m. ET
- Lineage Cell Therapeutics Reports Regeneration of Retinal Tissue in Patient Treated With OpRegen RPE Cells for Dry AMD With GAhttps://modernod.com/news/lineage-cell-therapeutics-reports-regeneration-of-retinal-tissue-in-patient-treated-with-opregen-rpe-cells-for-dry-amd-with-ga/2477845/Lineage Cell Therapeutics announced that restoration of retinal tissue was observed in a patient enrolled in a phase 1/2a study of its lead product candidate, OpRegen, a retinal pigment epithelium (RPE) cell transplant therapy in development for the treatment of dry age-related macular degenerati
- Gil Kliman, MD, and Tom Frinzi Appointed to STAAR Surgical Board of Directorshttps://modernod.com/news/gil-kliman-md-and-tom-frinzi-appointed-to-staar-surgical-board-of-directors/2477846/Staar Surgical announced the appointment of Gilbert H. Kliman, MD, Managing Partner, InterWest Partners, and Thomas G. Frinzi, former Worldwide President, Surgical, Johnson & Johnson Vision, to its board of directors, effective June 1, 2020. The appointment of Dr. Kliman and Mr. Frinzi brings
- BMC Virtual Spring Symposium About to Beginhttps://modernod.com/news/bmc-virtual-spring-symposium-to-begin-today/2477844/Bryn Mawr Communications’ virtual educational initiative, the BMC Virtual Spring Symposium, will begin today at 5 pm ET and run to 8:30 pm ET, and will resume tomorrow, May 30, from 10:00 am to 1:35 pm ET. More than 2,000 people have registered for the symposium. For more information
- In-Person ESCRS and Euretina Meetings Cancelled; Virtual Meetings Plannedhttps://modernod.com/news/escrs-and-euretina-meetings-cancelled-virtual-meetings-planned/2477843/Due to the COVID-19 pandemic, the in-person ESCRS and Euretina meetings, scheduled to take place in Amsterdam in October, have been cancelled. Instead, the 38th Congress of the ESCRS and the 20th Euretina Congress will be held in a virtual format. In a joint letter to their memberships, ES
- HOYA Surgical Optics Launches Ophthalmic New Joint Venture in Chinahttps://modernod.com/news/hoya-surgical-optics-launches-ophthalmic-new-joint-venture-in-china/2477825/In January, Hoya Surgical Optics (HSO) announced an agreement to partner with GeMax, a distributor partner since 2006. Last week, that new venture became a reality as operations opened up in Shanghai. This joint venture will introduce a broader range of currently available Hoya Surgical Op
- CooperVision to Host “Best Practices to Get You Back to Practice” Webinar Serieshttps://modernod.com/news/coopervision-to-host-best-practices-to-get-you-back-to-practice-webinar-series/2477811/In support of U.S. eye care professionals working to reopen their practices and rebuild their businesses, CooperVision will host a webinar series featuring its Best Practices program honorees, “Best Practices to Get You Back to Practice.” The series kicks off on Thursday, May 28. “Best Pra
- TearClear Appoints Dr. Amir Shojaei Chief Development Officerhttps://modernod.com/news/tearclear-appoints-dr-amir-shojaei-chief-development-officer/2477803/TearClear Corp. announced the appointment of Amir Shojaei, PharmD, PhD, as Chief Development Officer. Over his 23-year career, Dr. Shojaei has focus
- Market Scope: Premium IOLs Expected to Drive Market Growth Over the Next 5 Yearshttps://modernod.com/news/market-scope-premium-iols-expected-to-drive-market-growth-over-the-next-5-years/2477796/The revenue contribution of premium IOLs is expected to grow over the next 5 years as the number and different types of IOL designs offered to cataract and refractive patients seeking better visual outcomes increases, according to a Market Scope report. In 2019, premium IOLs accounted a th